Hepatitis C: Natural history, diagnosis, and management

American Journal of Health-System Pharmacy

Volumn 56, Issue 10, 1999, Pages 961-976

  Lam, Nancy P ^a,b  

^a AMGEN INC   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antivirals; Diagnosis; Enzyme inhibitors; Epidemiology; Hepatitis C; Immunomodulating agents; Interferon alfa 2a; Interferon alfa 2b; Interferon alfacon 1; Oligonucleotides; Protocols; Ribavirin; Ribozymes

Indexed keywords

CONSENSUS INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ANEMIA; ANTIBODY DETECTION; ANTIVIRAL ACTIVITY; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOTHERAPY; INFECTION RISK; LIVER BIOPSY; PREVALENCE; PRIORITY JOURNAL; TREATMENT PLANNING; UNITED STATES; VIRUS DETECTION; VIRUS TRANSMISSION;

EID: 0033562489     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/56.10.961     Document Type: Article

References (87)

1. Feinstone SM, Kapiklan AZ, Purcell RH et al. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med. 1975; 292:767-70.
2. Detre KM, Belle SH, Lombardero M. Liver transplantation for chronic viral hepatitis. Viral Hepatitis Rev. 1996; 2:219-28.
3. Sharara AI, Hunt CM, Hamilton JD. Hepatitis C. Ann Intern Med. 1996; 125:658-68.
4. Houghton M, Weiner A, Han J et al. Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology. 1991; 14:381-8.
5. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis. 1995; 15:41-63.
6. Simmonds P, Holmes EC, Cha TA et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol. 1993; 74:2391-9.
7. Simmonds P. Variability of hepatitis C virus. Hepatology. 1995; 21:570-83.
8. Mahaney K, Tedeschi V, Maertens G et al. Genotype analysis of hepatitis C virus in American patients. Hepatology. 1994; 20:1405-11.
9. Zein NN, Rakela J, Krawitt EL et al. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Ann Intern Med. 1996; 125: 634-9.
10. Weiner AJ, Geysen HM, Christopherson C et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci U S A. 1992; 89:3468-72.
11. Farci P, Shimoda A, Wong D et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A. 1996; 93:15394-9.
12. Weiner AJ, Brauer MJ, Rosenblatt J et al. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology. 1991; 180:842-8.
13. Alter MJ. Epidemiology of hepatitis C. Hepatology. 1997; 26(suppl 1):62S-5S.
14. National Institutes of Health consensus development conference panel statement: management of hepatitis C. Hepatology. 1997; 26(suppl 1):2S-10S.
15. Conry-Cantilena C, Vanraden M, Gibble J et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med. 1996; 334:1691-6.
16. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am. 1994; 23:437-55.
17. Alter HJ, Purcell RH, Shih JW et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med. 1989; 321:1494-500.
18. Barrera JM, Bruguera M, Guadalupe-Ercilla M et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology. 1995; 21:639-44.
19. Alter MJ, Hadler SC, Judson FN et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA. 1990; 264:2231-5.
20. Farci P, Alter HJ, Wong D et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med. 1991; 325:98-104.
21. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology. 1997; 26(suppl 1):15S-20S.
22. Hoofnagle JH, Carithers RL, Shapiro C et al. Fulminant hepatic failure: summary of a workshop. Hepatology. 1995; 21:240-52.
23. Seeff LB. Natural history of hepatitis C. Hepatology. 1997; 26(suppl 1):21S-8S.
24. Tong MJ, El-Farra NS, Reikes AR et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995; 332: 1463-6.
25. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology. 1997; 26(suppl 1):34S-8S.
26. Fattovich G, Giustina G, Degos F et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997; 112:463-72.
27. Miyakawa H, Sato C, Izumi N et al. Hepatitis C virus infection in alcoholic liver cirrhosis in Japan: its contribution to the development of hepatocellular carcinoma. Alcohol Alcohol. 1993;1A(suppl):85-90.
28. Okada S, Ishii H, Nose H et al. Effect of heavy alcohol intake on long-term results after curative resection of hepatitis C virus-related hepatocellular carcinoma. Jpn J Cancer Res. 1996; 87:867-73.
29. Mendenhall CL, Moritz T, Rouster S et al. Epidemiology of hepatitis C among veterans with alcoholic liver disease. Am J Gastroenterol. 1993; 88:1022-6.
30. Coelho-Little ME, Jeffers LJ, Bernstein DE et al. Hepatitis C virus in alcoholic patients with and without clinically apparent liver disease. Alcohol Clin Exp Res. 1995; 19:1173-6.
31. Caldwell SH, Li X, Rourk RM et al. Hepatitis C infection by polymerase chain reaction in alcoholics: false-positive ELISA results and the influence of infection on a clinical prognostic score. Am J Gastroenterol. 1993; 88:1016-21.
32. Cromie SL, Jenkins PJ, Bowden DS et al. Chronic hepatitis C: effect of alcohol on hepatic activity and viral titre. J Hepatol. 1996; 25:821-6.
33. Koff RS, Dienstag JL. Extrahepatic manifestations of hepatitis C and the association with alcoholic liver disease. Semin Liver Dis. 1995; 15:101-9.
34. Lunel F, Musset L. Hepatitis C virus infection and cryoglobulinemia. Viral Hepatitis Rev. 1996; 2:111-24.
35. Angello V, Chung RT, Kaplan LM. A role of hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992; 327:1490-5.
36. Johnson RJ, Gretch DR, Yamabe H et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med. 1993; 328:465-70.
37. DeCastro M, Sanchez J, Herrera JF et al. Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda. Hepatology. 1993; 17:551-7.
38. Gretch DR. Diagnostic tests for hepatitis C. Hepatology. 1997; 26(suppl 1):43S-7S.
39. Lok ASF, Gunaratnam NT. Diagnosis of hepatitis C. Hepatology. 1997; 26(suppl 1):48S-56S.
40. Haber MM, West A, Haber AD et al. Relationship of aminotransferases to liver histological status in chronic hepatitis C. Am J Gastroenterol. 1995; 90:1250-7.
41. Yano M, Kumada M, Kage M et al. The long-term pathological evolution of chronic hepatitis C. Hepatology. 1996; 23:1334-40.
42. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981; 1:431-5.
43. Poynard T, Leroy V, Cohard M et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology. 1996; 24:778-89.
44. Lindsay KL. Therapy of hepatitis C: overview. Hepatology. 1997; 26(suppl 1):71S-7S.
45. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med. 1997; 336:347-56.
46. Kasahara A, Hayashi N, Mochizuki K et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology. 1998; 27:1394-402.
47. Serfaty L, Aumaitre H, Chazouilleres O et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology. 1998; 27:1435-40.
48. Peters M. Mechanisms of action of interferons. Semin Liver Dis. 1989; 9:235-9.
49. Carithers RL Jr, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology. 1997; 26(suppl 1):83S-8S.
50. Lee WM. Therapy of hepatitis C: interferon alfa-2a trials. Hepatology. 1997; 26(suppl 1):89S-95S.
51. Keeffe EB, Hollinger FB, and the Consensus Interferon Study Group. Therapy of hepatitis C: consensus interferon trials. Hepatology. 1997; 26(suppl 1):101S-7S.
52. Ozes ON, Reiter ZVI, Klein S et al. A comparison of interferon-con 1 with natural recombinant interferons-alfa: antiviral, antiproliferative, and natural killer-inducing activities. J Interferon Res. 1992; 12:55-9.
53. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology. 1997; 26(suppl 1):112S-21S.
54. Renault PF, Hoofnagle JH, Park Y et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med. 1987; 147:1577-80.
55. Lisker-Melman M, Di Bisceglie AM, Usala SJ et al. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology. 1992; 102:2155-60.
56. Marazuela M, Garcia-Buey L, Gonzalez-Fernandez B et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-a therapy. Clin Endocrinol. 1996; 44:635-42.
57. Intron A package insert. Kenilworth, NJ: Schering-Plough Corporation; 1996 Jul.
58. Roferon A package insert. Nutley, NJ: Roche Laboratories; 1996 Oct.
59. Infergen package insert. Thousand Oaks, CA: Amgen Inc.; 1997 Oct.
60. Tong MJ, Blatt LM, McHutchison JG et al. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology. 1997; 26:1640-5.
61. Patterson J, Fernadez-Larson R. Molecular action of ribavirin. Rev infect Dis. 1990; 12:1132-46.
62. Di Bisceglie A, Conjeevaram J, Fried M et al. Ribavirin as therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995; 123:897-903.
63. Dusheiko G, Main J, Thomas HR et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol. 1996; 25:591-8.
64. Bodenheimer HC Jr, Lindsay KL, Davis GL et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology. 1997; 26:473-7.
65. Ning Q, Brown D, Parodo J et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fg12 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol. 1998; 160:3487-93.
66. Rebetron package insert. Kenilworth, NJ: Schering-Plough Corporation; 1998.
67. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. N Engl J Med. 1989; 321:1501-6.
68. Causse X, Godinot H, Chevallier M et al. Comparison of 1 or 3 mu of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology. 1991; 101:497-502.
69. Lau JYN, Mizokami M, Ohno T et al. Discrepancy between biochemical and virological responses to interferon-alfa in chronic hepatitis C. Lancet. 1993; 342:1208-9.
70. Manesis EK, Papaioannou C, Gioustozi A et al. Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: a 4-year follow-up of 211 patients. Hepatology. 1997; 26:734-9.
71. Tong MJ, Reddy KR, Lee WM et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Hepatology. 1997; 26:747-54.
72. Davis GL, Johnson JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology. 1997; 26(suppl 1):122S-7S.
73. Martinot-Pelgnoux M, Marcellin P, Pouteau M et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology. 1995; 22:1050-6.
74. Garson JA, Brillanti S, Whitby K et al. Analysis of clinical and virological factors associated with response to alpha interferon therapy in chronic hepatitis C. J Med Virol. 1995; 45:348-53.
75. Yamada G, Takahashi M, Endo H et al. Quantitative hepatitis C virus RNA and liver histology in chronic hepatitis C patients treated with interferon alfa. Gut. 1993; 34(suppl 2): S133-4.
76. Camps J, Garcia-Granero M, Riezo-Boj JI et al. Prediction of sustained remission of chronic hepatitis C after a 12-month course of alfa interferon. J Hepatol. 1994; 21:4-11.
77. Lindsay KL, Davis GL, Schiff ER et al. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatology. 1996; 24:1034-40.
78. McHutchinson JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998; 339:1485-92.
79. Poynard T, Marcellin P, Lee SS et al. Randomized trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 1998; 352:1426-32.
80. Alberti A, Chemello L, Noventa F et al. Therapy of hepatitis C: re-treatment with alpha-interferon. Hepatology. 1997; 26(suppl 1):137S-42S.
81. Heathcote EJL, Keeffe EB, Lee SS et al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology. 1998; 27:1136-43.
82. Davis GL, Esteban-Mur R, Rustgi V et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med. 1998; 339:1493-9.
83. Bennet WG, Inoue Y, Beck JR et al. Estimates of the cost-effectiveness of a single course of interferon-alfa2b in patients with histologically mild chronic hepatitis C. Ann Intern Med. 1997; 127:855-65.
84. Kim WR, Poterucha JJ, Hermans JE et al. Cost-effectiveness of 6 and 12 months of interferon-alfa therapy for chronic hepatitis C. Ann Intern Med. 1997; 127:866-74.
85. Kim WR, Poterucha JJ, Dickson ER et al. Economics analysis of interferon/ribavirin treatment in patients with chronic hepatitis C who relapse following initial interferon therapy. Gastroenterology. 1998; 114:A1274. Abstract.
86. Lam NP, Neumann AU, Gretch DR et al. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology. 1997; 26:226-31.
87. Weizsacker F, Wieland S, Kock J et al. Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants. Hepatology. 1997; 26:251-5.